News

Chan Zuckerberg Initiative Calls for Parkinson’s Research Proposals

The Chan Zuckerberg Initiative is accepting funding applications from researchers who want to do basic science projects on neurodegeneration. The goal is to increase scientists’ understanding of diseases such as Parkinson’s and Alzheimer’s and attract new talent and ideas. Grant recipients will become part of the CZI Neurodegeneration Challenge Network, an…

Wasp Venom Triggers Parkinson’s-Like Symptoms, Study Reports

The venom of the emerald cockroach wasp is capable of triggering Parkinson’s-like features, particularly problems controlling movement, a California study reports. Researchers said the findings on the venom’s toxins could lead to a better understanding of the mechanisms underlying Parkinson’s and new therapies. Their study, “Ampulexins: A New Family…

FDA Approves Osmolex, by Osmotica, to Treat Movement Problems in Parkinson’s and Other Adults

The U.S. Food and Drug Administration (FDA) has approved Osmolex ER (amantadine, extended release) to treat both Parkinson’s disease and therapy-induced extrapyramidal reactions in adults, or the movement and muscle-control problems that typify this disease and can be side effects of common medications. Osmodex ER, developed and marketed by Osmotica Pharmaceutical,…

Deep Brain Stimulation Improves Some Parkinson’s Symptoms But at Risk of Greater Apathy, Study Shows

Deep brain stimulation (DBS) is effective in improving several neuropsychiatric symptoms of Parkinson’s disease, but can lead to increased apathy in patients, research based on an observational clinical trial in patients suggests. The study, “Subthalamic stimulation and neuropsychiatric symptoms in Parkinson’s disease: results from a long-term follow-up cohort…

Emerald Health Pharmaceuticals’ Cannabinoid-Derived Compound Beneficial in Parkinson’s, Mouse Study Finds

Emerald Health Pharmaceuticals investigational EHP-102 (previously known as VCE-003.2), a patented compound derived from the non-psychotrophic cannabinoid called cannabigerol, has shown anti-inflammatory and neuroprotective properties in a mouse model of Parkinson’s disease. The study “Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s…